Replies to post #193088 on Biotech Values

[DewDiligence]

Santen/TCON drop AMD program after phase-2 failure:

https://www.globenewswire.com/news-release/2020/03/09/1997613/0/en/Santen-and-TRACON-Discontinue-Development-of-DE-122-for-Wet-Age-Related-Macular-Degeneration.html

The Phase 2a AVANTE clinical study is a randomized controlled trial that assessed visual acuity in wAMD patients following six monthly treatments with a combination of DE-122 and Lucentis or single agent Lucentis. Topline data indicated that DE-122 did not improve visual acuity when combined with Lucentis as compared to single agent Lucentis treatment, the primary endpoint of the trial.

Japan’s Santen Pharmaceuticals licensed the commercial rights to this program in 2014.